Free Newsletter
J&J nabs Topamax patent extension
Free newsletter via e-mail
Tools
Johnson & Johnson's epilepsy med Topamax won't go off patent in September as scheduled because the FDA has extended market exclusivity for one year based on a new pediatric indication for the med. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: